Loading organizations...
Weifang Zhongke Haichuang Equity Investment Partnership operates as a private equity firm, strategically deploying capital into promising companies primarily within China's burgeoning technology and biotechnology sectors. It focuses on identifying ventures with strong potential for industrialization and advanced research and development, providing the necessary financial backing to scale operations and enhance technological capabilities. The firm’s investment strategy centers on fostering growth and market expansion for its portfolio companies.
The firm was established in 2018, originating from Weifang, Shandong, China. Born from an understanding of the critical need for capital to fuel innovation and industrial transformation within specific high-growth industries, the partnership was formed to bridge the gap between groundbreaking research and market-ready applications. It positions itself as a key financial enabler for the next generation of Chinese enterprises.
Weifang Zhongke Haichuang serves as a crucial financial partner for growth-stage companies seeking to mature and expand their footprint. Its vision is to contribute to economic development by empowering enterprises that are at the forefront of technological advancement and industrial modernization. The firm aims to build a robust portfolio of companies that collectively drive forward China's strategic industries.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 16, 2020 | Enzymaster | $7.5M Series B | — | Caozhixing Junbo Equity Investment Partnership, Tibet Leimerious Venture Investment Partnership |